Table 3 Relative risk (HRs and 95% Confidence Intervals, CI) of breast cancer death in association with cumulative ASA dispensing defined as percent of time as exposed from breast cancer diagnosis to end of follow-up
Period | ASA dose | Cases | Controls | Model 1 | Model 2 |
|---|---|---|---|---|---|
HR (95% CI) | HR (95% CI) | ||||
E | - Up to 6 months before end of follow-up | ||||
(n = 1521) | (n = 3042) | ||||
0% | 1206 (79.3) | 2439 (80.2) | 1.00 | 1.00 | |
>0 – 25% | 23 (1.5) | 40 (1.3) | 1.18 (0.69; 1.99) | 1.28 (0.74; 2.21) | |
>25 – 50% | 22 (1.5) | 44 (1.4) | 1.02 (0.60; 1.74) | 1.18 (0.68; 2.04) | |
>50 – 75% | 29 (1.9) | 63 (2.1) | 0.94 (0.60; 1.47) | 0.99 (0.63; 1.58) | |
>75% | 241 (15.8) | 456 (15.0) | 1.08 (0.90; 1.30) | 1.05 (0.87; 1.28) | |
F | - Up to 3 months before end of follow-up | ||||
(n = 1661) | (n = 3322) | ||||
0% | 1298 (78.1) | 2622 (78.9) | 1.00 | 1.00 | |
>0 – 25% | 31 (1.9) | 48 (1.4) | 1.32 (0.83; 2.10) | 1.47 (0.91; 2.38) | |
>25 – 50% | 26 (1.6) | 60 (1.8) | 0.88 (0.55; 1.41) | 0.98 (0.60; 1.59) | |
>50 – 75% | 41 (2.4) | 74 (2.2) | 1.13 (0.76; 1.66) | 1.18 (0.80; 1.76) | |
>75% | 265 (16.0) | 518 (15.5) | 1.04 (0.88; 1.24) | 1.00 (0.83; 1.20) | |
G | - Up to end of follow-up | ||||
(n = 1661) | (n = 3322) | ||||
0% | 1266 (76.2) | 2572 (77.4) | 1.00 | 1.00 | |
>0 – 25% | 43 (2.6) | 57 (1.7) | 1.56 (1.04; 2.34) | 1.65 (1.08; 2.53) | |
>25 – 50% | 34 (2.0) | 64 (1.9) | 1.09 (0.71; 1.68) | 1.20 (0.77; 1.85) | |
>50 – 75% | 54 (3.3) | 89 (2.7) | 1.25 (0.88; 1.78) | 1.27 (0.89; 1.82) | |
>75% | 264 (15.9) | 540 (16.3) | 1.00 (0.84; 1.19) | 0.96 (0.80; 1.16) | |